Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP30 | Q70CQ3 | 10/20 | 0.47 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.46 |
| ▸ | ADORA1 | P30542 | 3/20 | 0.46 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.46 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.46 |
| ▸ | SCD | O00767 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4061915 | 0.85 | USP30 (0.46) | USP30ADORA3ADORA1ADORA2BADORA2A | |
| SCHEMBL4062469 | 0.84 | USP30 (0.63) | USP30ADORA3ADORA1ADORA2BADORA2A | |
| SCHEMBL13608170 | 0.81 | ADORA3 (0.41) | ADORA3ADORA1ADORA2BADORA2ANPC1 | |
| SCHEMBL4055566 | 0.77 | SCD (0.41) | USP30SCDCYP3A4TRPA1NPC1 | |
| SCHEMBL4054509 | 0.76 | USP30 (0.47) | USP30ADORA3ADORA1ADORA2BADORA2A | |
| SCHEMBL4058457 | 0.76 | ADORA1 (0.49) | USP30ADORA3ADORA1ADORA2BADORA2A | |
| SCHEMBL4051509 | 0.75 | SCD (0.63) | SCDCYP3A4TRPA1NPC1RAB9A | |
| SCHEMBL4051896 | 0.74 | SCD (0.47) | SCDCYP3A4 | |
| SCHEMBL4063852 | 0.74 | USP30 (0.70) | USP30 | |
| SCHEMBL4059431 | 0.74 | ADORA1 (0.50) | USP30ADORA3ADORA1ADORA2BADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7622479-B2 | Bicyclic derivative, its production and use | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-11-24 | — | — | US | disclosed |
| US-20050101647-A1 | Bicyclic derivative, its production and use | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2005-05-12 | — | — | US | disclosed |
| EP-1460067-A1 | BICYCLIC DERIVATIVE, PROCESS FOR PRODUCING THE SAME, AND USE | Takeda Chemical Industries, Ltd. (JP) | 2004-09-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050101647-A1 | Bicyclic derivative, its production and use | ABL1, SRC, PTK2B | USP30 2997/4885ADORA3 3829/4885ADORA1 3592/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.